BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
66
Data completeness
4/8 — Partial
SKYRIZI (risankizumab-rzaa) by AbbVie is interleukin-23 antagonists [moa]. First approved in 2019.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKYRIZI (risankizumab-rzaa) is a monoclonal antibody that blocks interleukin-23 (IL-23), a key driver of inflammatory disease pathways. It is approved for five indications: plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and hidradenitis suppurativa. The drug is administered by subcutaneous injection and represents a targeted biologic approach to moderate-to-severe inflammatory conditions.
Peak
SKYRIZI is at peak lifecycle with moderate competitive pressure (30/100), indicating stable team headcount and established commercial infrastructure at AbbVie.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (66)
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
Started Mar 2026
60 enrolled
Healthy Volunteer
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
Started Nov 2025
213 enrolled
Psoriasis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Started Oct 2025
200 enrolled
Ulcerative Colitis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Started Sep 2025
700 enrolled
Plaque Psoriasis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Started Jul 2025
120 enrolled
Ulcerative Colitis
Worked on SKYRIZI at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.